(19)
(11) EP 2 270 008 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.04.2013 Bulletin 2013/14

(45) Mention of the grant of the patent:
03.10.2012 Bulletin 2012/40

(21) Application number: 10175375.4

(22) Date of filing: 18.05.2006
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61P 35/00(2006.01)
A61P 11/06(2006.01)
 A61K 31/4188(2006.01)
A61P 29/00(2006.01)

(54)

8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors

8-Heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-on-Verbindungen als PI-3 kinase Hemmer

8-Hétéroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones comme inhibiteurs des PI-3 kinases

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK YU

(30) Priority: 20.05.2005 GB 0510390

(43) Date of publication of application:
05.01.2011 Bulletin 2011/01

(62) Application number of the earlier application in accordance with Art. 76 EPC:
06753710.0 / 1888578

(73) Proprietor: Novartis AG
4056 Basel (CH)

(72) Inventors:
  • Garcia-Echeverria, Carlos
    4052, Basel (CH)
  • Stauffer, Frédéric
    4153, Reinach (CH)
  • Furet, Pascal
    F-68800, Thann (FR)

(74) Representative: Gruber, Markus et al
Novartis Pharma AG Patent Department
4002 Basel
4002 Basel (CH)


(56) References cited: : 
WO-A1-2005/054237
WO-A2-03/097641
 WO-A1-2005/054238
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).